pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Cell Therapy · news · pharmadog
← back to Cell Therapy
News · Cell Therapy
308
stories
9h
As part of sales reorganization, Novo will cut 215 employees at US HQ
biospace
1d
Novartis details eczema win, autoimmune CAR-T efforts after rocky quarter
endpoints
1d
9 biotechs will cut at least half their California workforces
biospace
2d
Pfizer leaps into ‘in vivo’ CAR-T with latest China deal
biopharma dive
2d
Pfizer launches into autoimmune CAR T with China's Starna in up to $2.6B deal
biospace
2d
Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlight
biospace
3d
Genetix’s genetic medicines are officially profitable, with $327M in sales YTD
biospace
4d
Emerging biotech hubs step up as innovation economics evolve
biospace
4d
Deaths, failed trials and other recent setbacks in the autoimmune space
biospace
7d
Cellectis could cut 70% of workforce in shift to in vivo therapies
biospace
7d
Arrowhead’s Ionis problem, Kyverna’s next-gen end and more biotech earnings
biospace
7d
This week in charts: Brain drugs are back on venture capitalists’ minds
biopharma dive
7d
Cellectis will shed 70% of workforce as part of in vivo pivot
fiercebiotech
8d
Webinar: Optimizing Cell Therapy Manufacturing Efficiency with Cryopreserved Cells
biospace
8d
Biopharma layoffs rise YOY in October but sharply trend down for 2026
biospace
9d
Capricor parts ways with 10% of staff as FDA decision on DMD cell therapy nears
biospace
9d
Capricor ramps up manufacturing spend ahead of FDA decision for DMD therapy
biospace
9d
Novartis’ Zolgensma woes, BIO’s China plan, GLP-1s’ new safety warning, FDA’s stacked November
biospace
9d
Capricor, NextCure shed light on recent layoffs as they gear up for approval decision, merger
fiercebiotech
10d
FDA's rare disease framework faces its first real test in Capricor’s DMD drug
biospace
10d
Beam says base-edited sickle cell therapy succeeds in Phase 1/2 study
endpoints
10d
Beam preps FDA run for industry-first base-edited therapy after pivotal sickle cell success
biospace
10d
Beam’s sickle cell therapy results tee up potential Casgevy, Lyfgenia showdown
fiercebiotech
11d
Details from Novartis’ failed cardiovascular trial offer ‘little silver lining’ for rivals
biospace
14d
Verdicts for Summit/Akeso, Capricor, Vertex mark FDA’s stacked November
biospace
14d
There's more than one way to build a biotech
fiercebiotech
15d
Generate CEO sees ‘huge opportunity’ from using Claude to shorten CAR-T cell engines
fiercebiotech
17d
Vertex, ahead of FDA decision, calms fears surrounding kidney drug
biopharma dive
18d
Karyopharm, deep in debt, to sell itself in bankruptcy
biopharma dive
18d
Cell therapy investment grows as safety events rankle Big Pharma's CAR T autoimmune push
biospace
← prev
page 1 of 11
next →